AN ACT to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.
Summary
HB 1543 directs the North Dakota Legislative Management to study prescription drug pricing during the 2025-26 interim. The study is focused on the federal government’s “maximum fair price” for certain drugs, including how federal drug price negotiations under the Inflation Reduction Act of 2022 may affect prices paid in North Dakota.
The bill specifically requires the study to examine overlap between federally negotiated drug prices and drugs currently paid for by the Public Employees Retirement System, with an eye toward identifying usage patterns and possible cost savings for the state and consumers. The Legislative Management must also gather input from the Public Employees Retirement System, the insurance commissioner, the state board of pharmacy, and other stakeholders, then report findings and any recommended legislation to the 70th Legislative Assembly.
Impact
HB 1543 does not immediately change drug pricing law or create a new regulatory program; instead, it establishes a legislative study process that could lead to future legislation. Its practical effect is to place prescription drug affordability, federal price negotiation policy, and state employee health plan spending under formal review, potentially influencing future state purchasing, insurance, and pharmacy-related policy.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House and Senate by large margins, suggesting general agreement that prescription drug pricing is an important issue worth studying and that the state should evaluate whether federal drug price negotiations could produce savings for North Dakota and its residents.
Contention
Because the measure is only a study bill, there is limited evidence of major controversy in the available record. Any likely points of discussion would center on the scope of the study, the role of federal Inflation Reduction Act pricing rules, and whether the state should focus on potential savings for the Public Employees Retirement System and consumers. The near-unanimous votes indicate that any disagreements were minor rather than substantive.